MHRA has published an updated list of final determinations issued by the Borderline division within the agency. Details of the product names, the names of the companies to whom the determination notices were issued and brief details of the reasons for the determination are provided.
In the latest issue, MHRA discusses their decision regarding several HEMP-containing products, as well as glucosamine-containing products for joint pain and inflammation. MHRA has considered both types of products to fall within the definition of a medicinal product, given their indication for a serious adverse medical condition and potential to achieve their action through significant modification to human physiology.
Click to here to see the complete updated list of determinations.